Adocia SA (EPA:ADOC)
France
· Delayed Price · Currency is EUR 6.36
-0.10 (-1.55%)
Mar 6, 2026, 5:09 PM CET
Adocia Revenue
Adocia had revenue of 2.20M EUR in the half year ending June 30, 2025, a decrease of -43.63%. This brings the company's revenue in the last twelve months to 12.88M, up 258.42% year-over-year. In the year 2024, Adocia had annual revenue of 12.12M with 100.43% growth.
Revenue (ttm)
12.88M
Revenue Growth
+258.42%
P/S Ratio
9.83
Revenue / Employee
167.25K
Employees
77
Market Cap
126.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.12M | 6.08M | 100.43% |
| Dec 31, 2023 | 6.05M | -11.31M | -65.16% |
| Dec 31, 2022 | 17.36M | 11.31M | 186.72% |
| Dec 31, 2021 | 6.06M | -778.00K | -11.39% |
| Dec 31, 2020 | 6.83M | -1.30M | -16.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sensorion | 5.65M |
| Innate Pharma | 12.64M |
| MaaT Pharma | 3.92M |
| ABIONYX Pharma | 4.33M |
| OSE Immunotherapeutics | 1.78M |
| Valerio Therapeutics Société anonyme | 1.83M |
| Transgene | 7.58M |
| Cellectis | 70.36M |
Adocia News
- 1 year ago - Adocia raises €9.7 million in private placement, extending cash runway to Q2 2026 - Seeking Alpha